Worldwide Study Finder

Phase 2CompletedINTERVENTIONAL

A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo

ClinicalTrials.gov · NCT06131372 · Registry updated: 2026-09-24

Condition / research focus: Chronic Kidney Disease; Type 2 Diabetes; Obesity
Sponsor: Novo Nordisk A/S
Countries with listed sites: Argentina · Brazil · Canada · France · Greece · Hungary · India · Japan · Poland · Slovakia · Spain · Thailand · United States
Registry dates and results: Start: 2024-04-01. Completion: 2025-11-06 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Cagrilintide (drug)
Semaglutide (drug)
Placebo (drug)

Where the study takes place — 129 listed sites

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

Phase 1 / Phase 2RecruitingINTERVENTIONAL

Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease

ClinicalTrials.gov · NCT07651319 · Registry updated: 2026-09-23

Condition / research focus: Alzheimer Dementia (AD)
Sponsor: The Methodist Hospital Research Institute
Countries with listed sites: United States
Registry dates and results: Start: 2026-09-01. Completion: 2029-12 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

IL-2 (Aldesleukin) (drug)
Semaglutide Plus IL-2 (drug)
Placebo (drug)

Where the study takes place — 1 listed sites

Houston Methodist Research Institute
Houston, Texas, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

A Study Comparing the Effects of BGM0504 Injection and Semaglutide Injection on Obese Subjects.

ClinicalTrials.gov · NCT07836140 · Registry updated: 2026-09-23

Condition / research focus: Obesity / Overweight
Sponsor: Second Affiliated Hospital of Soochow University
Countries with listed sites: China
Registry dates and results: Start: 2024-04-22. Completion: 2026-04-30 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

semaglutide (drug)
BGM0504 Administered SC (drug)

Where the study takes place — 1 listed sites

The Second Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Weekly GLP-1 Receptor Agonists in Obese Individuals Without Diabetes

ClinicalTrials.gov · NCT07834398 · Registry updated: 2026-09-22

Condition / research focus: Non-diabetec Obesity; Obesity (Disorder)
Sponsor: Zagazig University
Countries with listed sites: Saudi Arabia
Registry dates and results: Start: 2025-11-14. Completion: 2026-04-21 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Dulaglutide (drug)
Semagludtide (drug)
Tirzepatide (drug)

Where the study takes place — 1 listed sites

New Najran General Hospital
Najran, Saudi Arabia
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2RecruitingINTERVENTIONAL

Semaglutide for Post-Smoking Cessation Weight Management

ClinicalTrials.gov · NCT06173778 · Registry updated: 2026-09-21

Condition / research focus: Obesity; Overweight; Cigarette Smoking
Sponsor: The University of Texas Health Science Center, Houston
Countries with listed sites: United States
Registry dates and results: Start: 2024-04-23. Completion: 2028-06-25 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

semaglutide 2.4mg (drug)
Placebo (drug)
Nicotine Replacement Therapy (NRT, nicotine patch) (drug)
Brief Smoking Cessation Counseling (behavioral)

Where the study takes place — 2 listed sites

The University of Texas at Austin
Austin, Texas, United States
Site recruitment: Recruiting
The University of Texas Health Science Center at Houston
Houston, Texas, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 3RecruitingINTERVENTIONAL

Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized Controlled Trial for Alcohol Use Disorder (CRAVE)

ClinicalTrials.gov · NCT07218354 · Registry updated: 2026-09-21

Condition / research focus: Alcohol Use Disorder
Sponsor: VA Office of Research and Development
Countries with listed sites: United States
Registry dates and results: Start: 2026-07-28. Completion: 2030-03-30 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Semaglutide (drug)
Placebo (drug)

Where the study takes place — 19 listed sites

VA Long Beach Healthcare System, Long Beach, CA
Long Beach, California, United States
Site recruitment: Recruiting
VA Palo Alto Health Care System, Palo Alto, CA
Palo Alto, California, United States
Site recruitment: Recruiting
VA Greater Los Angeles Healthcare System, West Los Angeles, CA
West Los Angeles, California, United States
Site recruitment: Recruiting
Orlando VA Healthcare System, Orlando, FL
Orlando, Florida, United States
Site recruitment: Recruiting
Atlanta VA Medical and Rehab Center, Decatur, GA
Decatur, Georgia, United States
Site recruitment: Not yet recruiting
Edward Hines Jr. VA Hospital, Hines, IL
Hines, Illinois, United States
Site recruitment: Recruiting
VA Ann Arbor Healthcare System, Ann Arbor, MI
Ann Arbor, Michigan, United States
Site recruitment: Recruiting
Minneapolis VA Health Care System, Minneapolis, MN
Minneapolis, Minnesota, United States
Site recruitment: Recruiting
Asheville VA Medical Center, Asheville, NC
Asheville, North Carolina, United States
Site recruitment: Recruiting
Durham VA Medical Center, Durham, NC
Durham, North Carolina, United States
Site recruitment: Recruiting
Louis Stokes VA Medical Center, Cleveland, OH
Cleveland, Ohio, United States
Site recruitment: Recruiting
VA Portland Health Care System, Portland, OR
Portland, Oregon, United States
Site recruitment: Recruiting
Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA
Philadelphia, Pennsylvania, United States
Site recruitment: Recruiting
Corporal Michael J. Crescenz VA Medical Center
Philadelphia, Pennsylvania, United States
Site recruitment: Recruiting
VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX
Dallas, Texas, United States
Site recruitment: Recruiting
Michael E. DeBakey VA Medical Center, Houston, TX
Houston, Texas, United States
Site recruitment: Recruiting
VA Salt Lake City Health Care System, Salt Lake City, UT
Salt Lake City, Utah, United States
Site recruitment: Recruiting
VA Puget Sound HCS - Seattle and Tacoma
Tacoma, Washington, United States
Site recruitment: Recruiting
William S. Middleton Memorial Veterans Hospital, Madison, WI
Madison, Wisconsin, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Comparative Effectiveness of Oral Semaglutide vs Sitagliptin Among Individuals With Heart Failure With Preserved Ejection Fraction (STEP-HFpEF DM ORAL)

ClinicalTrials.gov · NCT07390110 · Registry updated: 2026-09-21

Condition / research focus: Type 2 Diabetes; Heart Failure
Sponsor: Brigham and Women's Hospital
Countries with listed sites: United States
Registry dates and results: Start: 2026-01-24. Completion: 2026-06-30 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Oral semaglutide (drug)
Sitagliptin (drug)

Where the study takes place — 1 listed sites

Brigham and Women's Hospital
Boston, Massachusetts, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

UBT251 Injection Phase II (Type 2 Diabetes Mellitus) Study

ClinicalTrials.gov · NCT07163624 · Registry updated: 2026-09-21

Condition / research focus: Type 2 Diabetes Mellitus (T2DM)
Sponsor: The United Bio-Technology (Hengqin) Co., Ltd.
Countries with listed sites: China
Registry dates and results: Start: 2025-03-22. Completion: 2025-12-30 (may be estimated). No results posted in this registry response.

Products and interventions (5)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

UBT251 Injection 2.0 mg and UBT251 Injection Placebo (drug)
UBT251 Injection 4.0 mg (ID 0.5 mg) and UBT251 Injection Placebo (drug)
UBT251 Injection 4.0 mg (ID 1.0 mg) and UBT251 Injection Placebo (drug)
UBT251 Injection 6.0 mg and UBT251 Injection Placebo (drug)
Semaglutide Injection (Ozempic®) (drug)

Where the study takes place — 1 listed sites

The United Bio-Technology (Hengqin) Co., Ltd.
Zhuhai, Guangdong, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Comparative Study of Tirzepatide Versus Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

ClinicalTrials.gov · NCT06779929 · Registry updated: 2026-09-18

Condition / research focus: Type 2 Diabetes
Sponsor: Brigham and Women's Hospital
Countries with listed sites: United States
Registry dates and results: Start: 2024-11-01. Completion: 2026-03-01 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tirzepatide (drug)
Dulaglutide (drug)
Semaglutide (drug)

Where the study takes place — 1 listed sites

Brigham and Women's Hospital
Boston, Massachusetts, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Early Phase 1RecruitingINTERVENTIONAL

GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer

ClinicalTrials.gov · NCT07627191 · Registry updated: 2026-09-18

Condition / research focus: Pancreatic Cancer; Colorectal Cancer; Hepatocellular Carcinoma
Sponsor: University of Arizona
Countries with listed sites: United States
Registry dates and results: Start: 2026-10-10. Completion: 2028-06-30 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GLP1-RA (semaglutide) (drug)

Where the study takes place — 1 listed sites

University of Arizona Cancer Center
Tucson, Arizona, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase not reported / not applicableNot yet recruitingOBSERVATIONAL

Regulatory Post Marketing Surveillance (rPMS) Study of Rybelsus (Oral Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea

ClinicalTrials.gov · NCT05714683 · Registry updated: 2026-09-18

Condition / research focus: Diabetes Mellitus, Type 2
Sponsor: Novo Nordisk A/S
Countries with listed sites: No country reported
Registry dates and results: Start: 2027-01-31. Completion: 2027-10-31 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Semaglutide (drug) — also listed as: Rybelsus

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase not reported / not applicableNot yet recruitingOBSERVATIONAL

Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity

ClinicalTrials.gov · NCT07423481 · Registry updated: 2026-09-18

Condition / research focus: Obesity & Overweight
Sponsor: Nantes University Hospital
Countries with listed sites: France
Registry dates and results: Start: 2026-10-01. Completion: 2027-07-01 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

SEMAFOLLOW questionnaire (other)

Where the study takes place — 1 listed sites

Nantes university hospital
Nantes, France
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableRecruitingOBSERVATIONAL

Effects of Glucagon-like Peptide-1 (GLP-1) Agonist in Neuro-reproductive Function in Obese Adolescent Females With Polycystic Ovary Syndrome (PCOS)

ClinicalTrials.gov · NCT07169136 · Registry updated: 2026-09-18

Condition / research focus: Polycystic Ovarian Syndrome in Adolescent Females; Obesity (Disorder)
Sponsor: Nemours Children's Clinic
Countries with listed sites: United States
Registry dates and results: Start: 2025-09-11. Completion: 2026-12 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GLP-1 Receptor Agonists (drug)

Where the study takes place — 1 listed sites

Nemours Children's Clinic
Jacksonville, Florida, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide in Participants With Obesity (RESOLVE-2)

ClinicalTrials.gov · NCT07220629 · Registry updated: 2026-09-17

Condition / research focus: Obesity
Sponsor: Rezera (formerly NodThera Limited)
Countries with listed sites: United States
Registry dates and results: Start: 2025-10-02. Completion: 2026-08-21 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

NT-0796 (drug)
Placebo (drug)

Where the study takes place — 9 listed sites

Investigative Site
Mesa, Arizona, United States
Site recruitment: Not reported
Investigative Site
Hialeah, Florida, United States
Site recruitment: Not reported
Investigative Site
Jacksonville, Florida, United States
Site recruitment: Not reported
Investigative Site
Miami, Florida, United States
Site recruitment: Not reported
Investigative Site
Marrero, Louisiana, United States
Site recruitment: Not reported
Investigative Site
Columbus, Ohio, United States
Site recruitment: Not reported
Investigative Site
Seabrook, Texas, United States
Site recruitment: Not reported
Investigative Site
Salt Lake City, Utah, United States
Site recruitment: Not reported
Investigative Site
Manassas, Virginia, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2 / Phase 3Not yet recruitingINTERVENTIONAL

Semaglutide for the Prevention Of Post-Transplant Diabetes Mellitus

ClinicalTrials.gov · NCT06913023 · Registry updated: 2026-09-16

Condition / research focus: Kidney Transplant Recipient
Sponsor: University Health Network, Toronto
Countries with listed sites: Canada
Registry dates and results: Start: 2026-09-05. Completion: 2029-12-30 (may be estimated). No results posted in this registry response.

Products and interventions (5)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Semaglutide 0.25 mg (drug)
Semaglutide 0.5 mg (drug)
Semaglutide 1.0 mg (drug)
Semaglutide 1.7mg subcutaneous (drug)
Semaglutide 2.4 MG/0.75 ML Subcutaneous Solution [WEGOVY] (drug)

Where the study takes place — 2 listed sites

St. Paul's Hospital
Vancouver, British Columbia, Canada
Site recruitment: Not reported
Toronto General Hospital
Toronto, Ontario, Canada
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2Active, not recruitingINTERVENTIONAL

A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity

ClinicalTrials.gov · NCT07639021 · Registry updated: 2026-09-16

Condition / research focus: Obesity
Sponsor: Novo Nordisk A/S
Countries with listed sites: Puerto Rico · United States
Registry dates and results: Start: 2026-06-09. Completion: 2027-06-14 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

NNC0662-0419 (drug)
Semaglutide (drug)
NNC0662-0419 Placebo (drug)
Semaglutide placebo (drug)

Where the study takes place — 25 listed sites

Chambliss Clinical Trials, LLC
Montgomery, Alabama, United States
Site recruitment: Not reported
FDRC
Costa Mesa, California, United States
Site recruitment: Not reported
Los Angeles Institute for Metabolic Research
Los Angeles, California, United States
Site recruitment: Not reported
Encore Medical Research LLC
Hollywood, Florida, United States
Site recruitment: Not reported
South Broward Research LLC
Miramar, Florida, United States
Site recruitment: Not reported
West Orange Endocrinology
Ocoee, Florida, United States
Site recruitment: Not reported
Cedar-Crosse Research Center
Chicago, Illinois, United States
Site recruitment: Not reported
Great Lakes Clinical Trials
Chicago, Illinois, United States
Site recruitment: Not reported
Midwest Inst For Clin Res
Indianapolis, Indiana, United States
Site recruitment: Not reported
L-MARC Research Center
Louisville, Kentucky, United States
Site recruitment: Not reported
Endo And Metab Cons
Rockville, Maryland, United States
Site recruitment: Not reported
StudyMetrix Research LLC
City of Saint Peters, Missouri, United States
Site recruitment: Not reported
Great Lakes Medical Research
Westfield, New York, United States
Site recruitment: Not reported
KDCILM, LLC & Accellacare US, Inc.
Wilmington, North Carolina, United States
Site recruitment: Not reported
Family Practice Center of Wadsworth Inc.
Wadsworth, Ohio, United States
Site recruitment: Not reported
UPA Ctr Weight and Eating Dis
Philadelphia, Pennsylvania, United States
Site recruitment: Not reported
Clinical Res Collaborative
Cumberland, Rhode Island, United States
Site recruitment: Not reported
Holston Medical Group_Bristol
Bristol, Tennessee, United States
Site recruitment: Not reported
Holston Medical Group
Kingsport, Tennessee, United States
Site recruitment: Not reported
Clinical Research Associates
Nashville, Tennessee, United States
Site recruitment: Not reported
PlanIt Research, PLLC
Houston, Texas, United States
Site recruitment: Not reported
Pinnacle Clinical Research
San Antonio, Texas, United States
Site recruitment: Not reported
National Clin Res Inc.
Richmond, Virginia, United States
Site recruitment: Not reported
Rainier Clin Res Ctr Inc
Renton, Washington, United States
Site recruitment: Not reported
Isis Clinical Res. Ctr P.S.C.
Guaynabo, Puerto Rico
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3RecruitingINTERVENTIONAL

Semaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational Diabetes

ClinicalTrials.gov · NCT05569772 · Registry updated: 2026-09-15

Condition / research focus: Glucose Intolerance After a Recent History of Gestational Diabetes
Sponsor: Universitaire Ziekenhuizen KU Leuven
Countries with listed sites: Belgium
Registry dates and results: Start: 2023-09-14. Completion: 2030-05 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Semaglutide Pen Injector (drug) — also listed as: Ozempic
Semaglutide placebo (drug)

Where the study takes place — 13 listed sites

AZORG
Aalst, Belgium
Site recruitment: Recruiting
UZA
Antwerp, Belgium
Site recruitment: Recruiting
ZAS
Antwerp, Belgium
Site recruitment: Recruiting
AZ St Jan Brugge
Bruges, Belgium
Site recruitment: Recruiting
Erasme
Brussels, Belgium
Site recruitment: Recruiting
UZ Brussel
Brussels, Belgium
Site recruitment: Recruiting
Jan Yperman
Ieper, Belgium
Site recruitment: Recruiting
AZ Groeninge Kortrijk
Kortrijk, Belgium
Site recruitment: Recruiting
UZ Leuven
Leuven, Belgium
Site recruitment: Recruiting
CHU de Liège
Liège, Belgium
Site recruitment: Recruiting
Centre Hospitalier Mouscron
Mouscron, Belgium
Site recruitment: Recruiting
Vitaz
Sint-Niklaas, Belgium
Site recruitment: Recruiting
AZ Turnhout
Turnhout, Belgium
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Comparative Study of Different Weekly GLP-1 Receptor Agonists Among Diabetic and Non-Diabetic Patients: Clinical Trial

ClinicalTrials.gov · NCT07820111 · Registry updated: 2026-09-15

Condition / research focus: Obese Diabetics; Obese Non Diabetic
Sponsor: Zagazig University
Countries with listed sites: Saudi Arabia
Registry dates and results: Start: 2025-10-18. Completion: 2026-03-17 (may be estimated). No results posted in this registry response.

Products and interventions (6)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Dulaglutide 1.5 MG/ML (drug)
Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solution (drug)
Tirzepatide is administered as part of routine clinical care for obesity management, according to standard prescribing practices. Dosing and treatment duration are determined by the treating physician (drug)
Dulaglutide 0.75mg subcutaneous injection (drug)
Semaglutide 1.0 mg (drug)
Tirzepatide (Flexible titration) (drug)

Where the study takes place — 1 listed sites

Najran Health Cluster
Najran, Ksa, Saudi Arabia
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

ClinicalTrials.gov · NCT06045221 · Registry updated: 2026-09-15

Condition / research focus: Type 2 Diabetes
Sponsor: Eli Lilly and Company
Countries with listed sites: Argentina · China · Japan · Mexico · Puerto Rico · United States
Registry dates and results: Start: 2023-09-22. Completion: 2025-08-22 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Orforglipron (drug) — also listed as: LY3502970
Semaglutide (drug)

Where the study takes place — 131 listed sites

Absolute Clinical Research
Phoenix, Arizona, United States
Site recruitment: Not reported
San Fernando Valley Health Institute
Canoga Park, California, United States
Site recruitment: Not reported
Neighborhood Healthcare Institute of Health
Escondido, California, United States
Site recruitment: Not reported
Velocity Clinical Research, Gardena
Gardena, California, United States
Site recruitment: Not reported
Biopharma Informatic, LLC
Los Angeles, California, United States
Site recruitment: Not reported
Velocity Clinical Research, Westlake
Los Angeles, California, United States
Site recruitment: Not reported
Infinity Clinical Research - Norco
Norco, California, United States
Site recruitment: Not reported
Valley Clinical Trials, Inc.
Northridge, California, United States
Site recruitment: Not reported
Norcal Endocrinology & Internal Medicine
San Ramon, California, United States
Site recruitment: Not reported
Encompass Clinical Research
Spring Valley, California, United States
Site recruitment: Not reported
University Clinical Investigators, Inc.
Tustin, California, United States
Site recruitment: Not reported
New West Physicians Clinical Research
Golden, Colorado, United States
Site recruitment: Not reported
Connecticut Clinical Research - Cromwell
Cromwell, Connecticut, United States
Site recruitment: Not reported
Clinical Research of West Florida, Inc. (Clearwater)
Clearwater, Florida, United States
Site recruitment: Not reported
South Florida Clinical Research Institute
Margate, Florida, United States
Site recruitment: Not reported
Miami Dade Medical Research Institute, LLC
Miami, Florida, United States
Site recruitment: Not reported
West Orange Endocrinology
Ocoee, Florida, United States
Site recruitment: Not reported
Latin Clinical Trial Center Florida
Tamarac, Florida, United States
Site recruitment: Not reported
Clinical Research of West Florida
Tampa, Florida, United States
Site recruitment: Not reported
Metabolic Research Institute, Inc.
West Palm Beach, Florida, United States
Site recruitment: Not reported
Balanced Life Health Care Solutions/SKYCRNG
Lawrenceville, Georgia, United States
Site recruitment: Not reported
Clinical Research Atlanta
Stockbridge, Georgia, United States
Site recruitment: Not reported
North Georgia Clinical Research
Woodstock, Georgia, United States
Site recruitment: Not reported
Northwest Clinical Trials
Boise, Idaho, United States
Site recruitment: Not reported
Family First Medical Center
Idaho Falls, Idaho, United States
Site recruitment: Not reported
American Health Network of Indiana, LLC - Greenfield
Greenfield, Indiana, United States
Site recruitment: Not reported
Velocity Clinical Research, Valparaiso
Valparaiso, Indiana, United States
Site recruitment: Not reported
Cotton O'Neil Diabetes & Endocrinology
Topeka, Kansas, United States
Site recruitment: Not reported
Tekton Research, Inc
Wichita, Kansas, United States
Site recruitment: Not reported
DelRicht Research
New Orleans, Louisiana, United States
Site recruitment: Not reported
Joslin Diabetes Center
Boston, Massachusetts, United States
Site recruitment: Not reported
Revival Research Institute, LLC
Dearborn, Michigan, United States
Site recruitment: Not reported
SKY Integrative Medical Center/SKYCRNG
Ridgeland, Mississippi, United States
Site recruitment: Not reported
Kansas City Research Institute
Kansas City, Missouri, United States
Site recruitment: Not reported
Logan Health Research
Kalispell, Montana, United States
Site recruitment: Not reported
Wr-Crcn, Llc
Las Vegas, Nevada, United States
Site recruitment: Not reported
Premier Research
Trenton, New Jersey, United States
Site recruitment: Not reported
Albany Medical College, Division of Community Endocrinology
Albany, New York, United States
Site recruitment: Not reported
Ellipsis Research Group - Brooklyn - 7th Street
Brooklyn, New York, United States
Site recruitment: Not reported
Great Lakes Medical Research, LLC
Westfield, New York, United States
Site recruitment: Not reported
PharmQuest Life Sciences, LLC
Greensboro, North Carolina, United States
Site recruitment: Not reported
Lucas Research, Inc
Morehead City, North Carolina, United States
Site recruitment: Not reported
Accellacare - Piedmont
Statesville, North Carolina, United States
Site recruitment: Not reported
Wake Forest University Baptist Medical Center (WFUBMC)
Winston-Salem, North Carolina, United States
Site recruitment: Not reported
Aventiv Research Inc
Columbus, Ohio, United States
Site recruitment: Not reported
Tekton Research, Inc
Moore, Oklahoma, United States
Site recruitment: Not reported
Alliance for Multispecialty Research, LLC
Norman, Oklahoma, United States
Site recruitment: Not reported
The Corvallis Clinic, P.C.
Corvallis, Oregon, United States
Site recruitment: Not reported
Heritage Valley Medical Group, Inc.
Beaver, Pennsylvania, United States
Site recruitment: Not reported
Preferred Primary Care Physicians, Preferred Clinical Research (Ofc 18)
Pittsburgh, Pennsylvania, United States
Site recruitment: Not reported
The Research Center of The Upstate
Greenville, South Carolina, United States
Site recruitment: Not reported
New Phase Research and Development
Knoxville, Tennessee, United States
Site recruitment: Not reported
Clinical Neuroscience Solutions Inc.
Memphis, Tennessee, United States
Site recruitment: Not reported
Velocity Clinical Research, Austin
Austin, Texas, United States
Site recruitment: Not reported
Velocity Clinical Research, Dallas
Dallas, Texas, United States
Site recruitment: Not reported
Diabetes and Thyroid Center of Ft. Worth
Fort Worth, Texas, United States
Site recruitment: Not reported
Juno Research
Houston, Texas, United States
Site recruitment: Not reported
Endocrine Ips, Pllc
Houston, Texas, United States
Site recruitment: Not reported
Clear Brook Medical Associates
Houston, Texas, United States
Site recruitment: Not reported
Southern Endocrinology Associates
Mesquite, Texas, United States
Site recruitment: Not reported
Texas Valley Clinical Research
Weslaco, Texas, United States
Site recruitment: Not reported
Synexus Clinical Research US, Inc.
Salt Lake City, Utah, United States
Site recruitment: Not reported
Eastside Research Associates
Redmond, Washington, United States
Site recruitment: Not reported
Rainier Clinical Research Center
Renton, Washington, United States
Site recruitment: Not reported
Centro de Investigaciones Metabólicas (CINME)
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
Site recruitment: Not reported
CIMeL
Lanus, Buenos Aires, Argentina
Site recruitment: Not reported
Centro de Investigaciones Médicas Mar del Plata
Mar del Plata, Buenos Aires, Argentina
Site recruitment: Not reported
Policlinica Red OMIP
Mar del Plata, Buenos Aires, Argentina
Site recruitment: Not reported
Consultorio de Investigación Clínica EMO SRL
Buenos Aires, Buenos Aires F.D., Argentina
Site recruitment: Not reported
CIPREC
Buenos Aires, Buenos Aires F.D., Argentina
Site recruitment: Not reported
Centro Médico Viamonte
Buenos Aires, Buenos Aires F.D., Argentina
Site recruitment: Not reported
Instituto Centenario
CABA, Buenos Aires F.D., Argentina
Site recruitment: Not reported
Centro de Salud e Investigaciones Médicas
Santa Rosa, La Pampa Province, Argentina
Site recruitment: Not reported
INECO Neurociencias Oroño
Rosario, Santa Fe Province, Argentina
Site recruitment: Not reported
Instituto de Especialidades de la Salud Rosario
Rosario, Santa Fe Province, Argentina
Site recruitment: Not reported
Instituto Médico Catamarca IMEC
Rosario, Santa Fe Province, Argentina
Site recruitment: Not reported
Instituto Médico Fundación Grupo Colaborativo Rosario Investigación y Prevención Medica
Rosario, Santa Fe Province, Argentina
Site recruitment: Not reported
Fundacion Estudios Clinicos
Rosario, Santa Fe Province, Argentina
Site recruitment: Not reported
Instituto de Investigaciones Clínicas Córdoba
Córdoba, Argentina
Site recruitment: Not reported
Instituto Médico DAMIC
Córdoba, Argentina
Site recruitment: Not reported
Sanatorio Norte
Santiago del Estero, Argentina
Site recruitment: Not reported
Beijing Pinggu District Hospital
Beijing, Beijing Municipality, China
Site recruitment: Not reported
Chongqing General Hospital
Chongqing, Chongqing Municipality, China
Site recruitment: Not reported
Shunde Hospital of Southern Medical Univesity
Foshan, Guangdong, China
Site recruitment: Not reported
Huizhou Municipal Central Hospital
Huizhou, Guangdong, China
Site recruitment: Not reported
The Fourth Hospital of Harbin Medical University
Harbin, Heilongjiang, China
Site recruitment: Not reported
The First Affiliated Hospital of Henan University of Science &Technology
Luoyang Shi, Henan, China
Site recruitment: Not reported
Nanyang First People's Hospital
Nanyang, Henan, China
Site recruitment: Not reported
The Second Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Site recruitment: Not reported
Nanjing First Hospital
Nanjing, Jiangsu, China
Site recruitment: Not reported
The Second Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China
Site recruitment: Not reported
Affiliated Hospital of Jiangsu University
Zhenjiang, Jiangsu, China
Site recruitment: Not reported
Jiangxi Pingxiang People's Hospital
Pingxiang, Jiangxi, China
Site recruitment: Not reported
Dalian Municipal Central Hospital Affiliated of Dalian Medical University
Dalian, Liaoning, China
Site recruitment: Not reported
Jinan Central Hospital
Jinan, Shandong, China
Site recruitment: Not reported
Shanghai Sixth People's Hospital
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported
Pudong New Area People's Hospital Shanghai
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported
West China Hospital of Sichuan University
Chengdu, Sichuan, China
Site recruitment: Not reported
First Affiliated Hospital of Kunming Medical University
Kunming, Yunnan, China
Site recruitment: Not reported
Zhejiang Hospital
Hangzhou, Zhejiang, China
Site recruitment: Not reported
Huzhou Central Hospital
Huzhou, Zhejiang, China
Site recruitment: Not reported
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China
Site recruitment: Not reported
Mikannohana Clinic, Diabetes, Endocrinology and Metabolism
Matsuyama, Ehime, Japan
Site recruitment: Not reported
Manda Memorial Hospital
Sapporo, Hokkaido, Japan
Site recruitment: Not reported
Nakamoto Internal Medicine Clinic
Mito, Ibaraki, Japan
Site recruitment: Not reported
Nakakinen clinic
Naka, Ibaraki, Japan
Site recruitment: Not reported
Ohishi Internal Medicine Clinic
Tsuchiura, Ibaraki, Japan
Site recruitment: Not reported
Takai Internal Medicine Clinic
Kamakura-shi, Kanagawa, Japan
Site recruitment: Not reported
Shiraiwa Medical Clinic
Kashihara, Osaka, Japan
Site recruitment: Not reported
Medical Corporation Sato Medical clinic
Ootaku, Tokyo, Japan
Site recruitment: Not reported
Gifu University Hospital
Gifu, Japan
Site recruitment: Not reported
Centro de Investigacion Medica Integral
Guadalajara, Jalisco, Mexico
Site recruitment: Not reported
Instituto Jalisciense de Investigacion en Diabetes y Obesidad
Guadalajara, Jalisco, Mexico
Site recruitment: Not reported
CICEJ Centro de Investigación Clínica Endocrinológica de Jalisco S.C
Guadalajara, Jalisco, Mexico
Site recruitment: Not reported
Private Practice - Dr. Arechavaleta Granell Maria del Rosario
Guadalajara, Jalisco, Mexico
Site recruitment: Not reported
Virgen Cardiovascular Research SC
Guadalajara, Jalisco, Mexico
Site recruitment: Not reported
Centro de Investigacion Medica de Occidente, S.C.
Zapopan, Jalisco, Mexico
Site recruitment: Not reported
Caimed Investigacion En Salud S.A. de C.V.
Mexico City, Mexico City, Mexico
Site recruitment: Not reported
Centro Especializado En Diabetes, Obesidad Y Prevencion De Enfermedades Cardiovasculares
Mexico City, Mexico City, Mexico
Site recruitment: Not reported
Cardiolink Clin Trials
Monterrey, Nuevo León, Mexico
Site recruitment: Not reported
Unidad biomedica avanzada monterrey
Monterrey, Nuevo León, Mexico
Site recruitment: Not reported
Clínica García Flores SC
Monterrey, Nuevo León, Mexico
Site recruitment: Not reported
Eukarya PharmaSite
Monterrey, Nuevo León, Mexico
Site recruitment: Not reported
Hospital Universitario "Dr. Jose Eleuterio Gonzalez"
Monterrey, Nuevo León, Mexico
Site recruitment: Not reported
Centro de investigación y control metabólico
San Nicolás de los Garza, Nuevo León, Mexico
Site recruitment: Not reported
Centro Para El Desarrollo de La Medicina Y de Asistencia Medica Especializada S.C.
Culiacán, Sinaloa, Mexico
Site recruitment: Not reported
Lahoja. Asociacion Para La Investigacion Y La Farmacovigilancia
Durango, Mexico
Site recruitment: Not reported
Isis Clinical Research Center
Guaynabo, PR, Puerto Rico
Site recruitment: Not reported
Mgcendo Llc
San Juan, PR, Puerto Rico
Site recruitment: Not reported
Research and Cardiovascular Corp.
Ponce, Puerto Rico
Site recruitment: Not reported
Latin Clinical Trial Center
San Juan, Puerto Rico
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Early Phase 1Not yet recruitingINTERVENTIONAL

Assessing Heart and Brain Metabolism in Type II Diabetes Mellitus Patients Using Carbon-13 MRI

ClinicalTrials.gov · NCT07820722 · Registry updated: 2026-09-15

Condition / research focus: Diabete Type 2
Sponsor: Sunnybrook Health Sciences Centre
Countries with listed sites: No country reported
Registry dates and results: Start: 2026-10-01. Completion: 2029-08-01 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

C13 Hyperpolarized pyruvate injection (drug)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Worldwide Study Finder

Find a study

Registry search results

A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo

Explore the world’s study registries

Worldwide

Africa

Americas

Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease

A Study Comparing the Effects of BGM0504 Injection and Semaglutide Injection on Obese Subjects.

Weekly GLP-1 Receptor Agonists in Obese Individuals Without Diabetes

Semaglutide for Post-Smoking Cessation Weight Management

Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized Controlled Trial for Alcohol Use Disorder (CRAVE)

Comparative Effectiveness of Oral Semaglutide vs Sitagliptin Among Individuals With Heart Failure With Preserved Ejection Fraction (STEP-HFpEF DM ORAL)

UBT251 Injection Phase II (Type 2 Diabetes Mellitus) Study

Comparative Study of Tirzepatide Versus Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer

Regulatory Post Marketing Surveillance (rPMS) Study of Rybelsus (Oral Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea

Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity

Effects of Glucagon-like Peptide-1 (GLP-1) Agonist in Neuro-reproductive Function in Obese Adolescent Females With Polycystic Ovary Syndrome (PCOS)

Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide in Participants With Obesity (RESOLVE-2)

Semaglutide for the Prevention Of Post-Transplant Diabetes Mellitus

A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity

Semaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational Diabetes

Comparative Study of Different Weekly GLP-1 Receptor Agonists Among Diabetic and Non-Diabetic Patients: Clinical Trial

A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

Assessing Heart and Brain Metabolism in Type II Diabetes Mellitus Patients Using Carbon-13 MRI

Asia

Middle East

Europe

Oceania